UAB 17127-A Phase 1b Trial of Fulvestrant, Palbociclib (CDK4/6 inhibitor) and Erdafitinib (JNJ-42756493, Pan-FGFR Tyrosine Kinase Inhibitor) in ER+/HER2–/FGFR-Amplified Metastatic Breast Cancer (MBC)

Grant

Awarded By

Total Award Amount

  • 47185.00

    • Direct Costs

  • 36297.00

    • Sponsor Award Id

    • Contributor

  • Ahmed Elkhanany   Investigator  
  • Erica Stringer-Reasor M.D.   Principal Investigator  
  • Gabrielle Rocque M.D.   Investigator